The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome prior to alloHSCT.

The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation ...

The FDA approved treosulfan in combination with fludarabine as preparation for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult and pediatric patients with acute myeloid ...

Treosulfan (Grafapex) was approved in Canada in June 2021 for the same use and is marketed under the brand name Trecondyv.

The FDA approved treosulfan (Grafapex) with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in patients ages 1 year and older with acute myeloid leukemia ...

Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic stem cell transplantation.

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

After a delayed approval, treosulfan’s manufacturer is hopeful the alkylating agent will become the new gold standard in the United States.

The FDA has approved Grafapex (treosulfan) for use in combination with fludarabine as a preparative regimen for allogeneic HSCT in patients aged 1 year and older with AML or MDS.

A new research paper titled "ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells" has been published in Oncotarget. ABT199 ...